Medical education right at your fingertips

Enhance your
clinical expertise
anytime, anywhere

AusDoc offers 24/7 free access to practical, real-world medical education designed for busy doctors. Dive into our extensive library of How to Treat resources and interactive Spot Diagnosis quizzes, tailored to enhance your knowledge and sharpen your skills for handling the presentations you encounter in everyday practice.

Gain practical insights and stay prepared for every patient interaction—all while earning accredited CPD hours at no cost.

Join AusDoc and take your clinical practice to the next level.

Why use AusDoc CPD?

Start Course
0 Sections

Abnormal results in haematology
This How To Treat course and quiz are approved for 0.5 hour EA and 0.5 hour RP by the RACGP CPD and ACRRM PDP programs for the 2023-2025 triennium. Please read the educational material provided and then complete the quiz and evaluation to earn your Statement of Completion. tr, th { font-size: 16px; font-weight: 400; color: #ffff; padding-top: 12px; } img.wp-image-118064 { margin-right: 300px; padding-bottom: 8px; } img.wp-image-118063 { padding-bottom: 8px; } @media only screen and (max-width: 600px) { .table1{ position: absolute; } } @media only screen and (max-width: 600px) { img.wp-image-118064{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118062{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118063{ width: 300px; } } @media only screen and (max-width: 600px) { th.table2 { padding-top: 320px; } }

RACGP Activity Number: 441828 ACRRM Activity Number: 28374

Key points
- Microcytosis is commonly due to thalassaemia and iron deficiency. The diagnosis of thalassaemia in asymptomatic individuals is generally of no consequence to the patient but may have significant reproductive implications in individuals of child-bearing age if their partner also carries a globin-gene mutation.
- Investigate macrocytosis in individuals where a cause is not evident on clinical assessment; consider haematological malignancies and cobalamin (B12) or folate deficiency in patients not taking drugs which can cause macrocytosis.
- Testing for homocysteine or methylmalonic acid is more sensitive for cobalamin deficiency than measuring serum B12 levels.
- Although a low ferritin is specific for iron deficiency, elevated ferritin is not limited to iron overload and may be seen in several inflammatory states, malignancies, or with liver injury.
- Although most patients with a paraprotein will never develop cancer, these patients will generally require serial testing to detect the small subset who progress to develop myeloma.
Start Course
0 Sections

Achilles tendinopathy
This How To Treat course and quiz are approved for 0.5 hour EA and 0.5 hour RP by the RACGP CPD and ACRRM PDP programs for the 2023-2025 triennium. Please read the educational material provided and then complete the quiz and evaluation to earn your Statement of Completion. tr, th { font-size: 16px; font-weight: 400; color: #ffff; padding-top: 12px; } img.wp-image-118064 { margin-right: 300px; padding-bottom: 8px; } img.wp-image-118063 { padding-bottom: 8px; } @media only screen and (max-width: 600px) { .table1{ position: absolute; } } @media only screen and (max-width: 600px) { img.wp-image-118064{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118062{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118063{ width: 300px; } } @media only screen and (max-width: 600px) { th.table2 { padding-top: 320px; } }

RACGP Activity Number: 417753 ACRRM Activity Number: 28338

Key points
- Achilles tendinopathy is not primarily an inflammatory condition; treatment with rest, ice and anti-inflammatories is not an effective long-term solution.
- The clinical presentation of Achilles tendinopathy is caused by a change in load, which can be subtle or obvious; it is critical to identify this load change so the load can be ameliorated to reduce symptoms.
- Imaging and palpation tenderness are not diagnostic of Achilles tendinopathy; reproduction of pain on loading tests are the best indicators.
- Exercised-based treatment is the gold standard but can take weeks to months to return the person to full activity.
- Passive treatments may offer short-term pain relief; injection therapies are not supported by evidence and do not address the underlying dysfunction.
Start Course
0 Sections

Acne vulgaris
This How To Treat course and quiz are approved for 0.5 hour EA and 0.5 hour RP by the RACGP CPD and ACRRM PDP programs for the 2023-2025 triennium. Please read the educational material provided and then complete the quiz and evaluation to earn your Statement of Completion. tr, th { font-size: 16px; font-weight: 400; color: #ffff; padding-top: 12px; } img.wp-image-118064 { margin-right: 300px; padding-bottom: 8px; } img.wp-image-118063 { padding-bottom: 8px; } @media only screen and (max-width: 600px) { .table1{ position: absolute; } } @media only screen and (max-width: 600px) { img.wp-image-118064{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118062{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118063{ width: 300px; } } @media only screen and (max-width: 600px) { th.table2 { padding-top: 320px; } }

RACGP Activity Number: 634185 ACRRM Activity Number: 31606

Key points
- First-line treatment for mild acne includes topical mono or combined therapy; azaleic acid and topical retinoids are options for patients with concurrent hyperpigmentation.
- First-line treatment for moderate-severe acne includes combined topical therapy with an oral antibiotic.
- Treatment of acne yields results as early as three months; consistent adherence to treatment is key. However, in the absence of response at three months or deterioration prior, referral to a specialist dermatologist is indicated. The PBS does not mandate a time period for which treatments must be trialled before starting oral isotretinoin.
- Consider early specialist referral for consideration of oral isotretinoin in the event of scarring or severe psychological distress.
- Relapses of acne do occur after completing a course of oral isotretinoin and may require a second course. Encourage patients to re-present to their dermatologist if this occurs.
- Do not forget underlying pathologies, hygiene and lifestyle factors, or medications which can exacerbate acne. These may be easier to treat than the acne itself.
Start Course
0 Sections

Acute corneal conditions
This How To Treat course and quiz are approved for 0.5 hour EA and 0.5 hour RP by the RACGP CPD and ACRRM PDP programs for the 2023-2025 triennium. Please read the educational material provided and then complete the quiz and evaluation to earn your Statement of Completion. tr, th { font-size: 16px; font-weight: 400; color: #ffff; padding-top: 12px; } img.wp-image-118064 { margin-right: 300px; padding-bottom: 8px; } img.wp-image-118063 { padding-bottom: 8px; } @media only screen and (max-width: 600px) { .table1{ position: absolute; } } @media only screen and (max-width: 600px) { img.wp-image-118064{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118062{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118063{ width: 300px; } } @media only screen and (max-width: 600px) { th.table2 { padding-top: 320px; } }

RACGP Activity Number: 805444 ACRRM Activity Number: 32910

Key points
- Most corneal conditions can be diagnosed with a careful history of the symptoms and examination for key signs.
- A measurement of the level of vision is mandatory.
- The cornea is accessible with a good light and magnification, aided by topical fluorescein for assessing epithelial defects and aqueous leaks.
- Once a diagnosis is formulated, the appropriate management can be instigated, and follow-up determined by the severity of the condition.
- There is a low threshold for referral for ophthalmic care as the progression of disease can lead to permanent scarring and loss of vision.
Start Course
0 Sections

Acute coronary syndrome
This How To Treat course and quiz are approved for 0.5 hour EA and 0.5 hour RP by the RACGP CPD and ACRRM PDP programs for the 2023-2025 triennium. Please read the educational material provided and then complete the quiz and evaluation to earn your Statement of Completion. tr, th { font-size: 16px; font-weight: 400; color: #ffff; padding-top: 12px; } img.wp-image-118064 { margin-right: 300px; padding-bottom: 8px; } img.wp-image-118063 { padding-bottom: 8px; } @media only screen and (max-width: 600px) { .table1{ position: absolute; } } @media only screen and (max-width: 600px) { img.wp-image-118064{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118062{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118063{ width: 300px; } } @media only screen and (max-width: 600px) { th.table2 { padding-top: 320px; } }

RACGP Activity Number: 522162 ACRRM Activity Number: 30213

Key points
- Cardiac ischaemic chest pain is described as a central pressure sensation on the chest, radiating to the jaw and into the left arm.
- The pain may be retrosternal, deep, diffuse and difficult to localise; it is often associated with nausea and vomiting, fatigue, syncope, diaphoresis, lightheadedness or vague abdominal symptoms in high-risk patients.
- Patients with traditional risk factors, and those with rheumatoid arthritis, HIV/AIDS, chronic kidney disease, non-alcoholic fatty liver disease, mental health disorders, a history of premature menopause or high-risk conditions during pregnancy, are at high risk.
- Initial management in suspected ACS is aspirin and sublingual nitroglycerin (GTN); do not provide antiplatelet or anticoagulation therapy or other therapies such as beta blockers until the diagnosis is confirmed.
- Troponin testing should not delay referral to hospital, and is not indicated in asymptomatic patients.
- Secondary prevention, such as healthy behaviours, intensive risk-factor modification and adherence to proven cardioprotective medications, are critical to reducing new vascular events in patients discharged from hospital with a confirmed diagnosis of ACS.
Start Course
0 Sections

Acute ketoacidosis
This How To Treat course and quiz are approved for 0.5 hour EA and 0.5 hour RP by the RACGP CPD and ACRRM PDP programs for the 2023-2025 triennium. Please read the educational material provided and then complete the quiz and evaluation to earn your Statement of Completion. tr, th { font-size: 16px; font-weight: 400; color: #ffff; padding-top: 12px; } img.wp-image-118064 { margin-right: 300px; padding-bottom: 8px; } img.wp-image-118063 { padding-bottom: 8px; } @media only screen and (max-width: 600px) { .table1{ position: absolute; } } @media only screen and (max-width: 600px) { img.wp-image-118064{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118062{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118063{ width: 300px; } } @media only screen and (max-width: 600px) { th.table2 { padding-top: 320px; } }

RACGP Activity Number: 600850 ACRRM Activity Number: 31236

Key points
- Diabetic ketoacidosis (DKA) is common with type 1 diabetes, affecting up to one in six adults with type 1 diabetes over a 10-year period.
- Euglycaemic ketoacidosis (EKA) is a rare condition triggered by extreme metabolic stress in ketosis-prone individuals (eg, those with diabetes, pregnancy, or who use SGLT2 inhibitors).
- Consider ketoacidosis in the differential diagnosis of sick individuals presenting with non-specific gastrointestinal symptoms, especially those with diabetes.
- Ketoacidosis is easily identified by elevated blood ketone concentrations, which should trigger an emergency plan and urgent hospitalisation.
Start Course
0 Sections

Acute sporting knee injuries
This How To Treat course and quiz are approved for 0.5 hour EA and 0.5 hour RP by the RACGP CPD and ACRRM PDP programs for the 2023-2025 triennium. Please read the educational material provided and then complete the quiz and evaluation to earn your Statement of Completion. tr, th { font-size: 16px; font-weight: 400; color: #ffff; padding-top: 12px; } img.wp-image-118064 { margin-right: 300px; padding-bottom: 8px; } img.wp-image-118063 { padding-bottom: 8px; } @media only screen and (max-width: 600px) { .table1{ position: absolute; } } @media only screen and (max-width: 600px) { img.wp-image-118064{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118062{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118063{ width: 300px; } } @media only screen and (max-width: 600px) { th.table2 { padding-top: 320px; } }

RACGP Activity Number: 1033805 ACRRM Activity Number: 34920

Key points
- Acute knee injuries are common in pivoting and contact sports.
- A thorough history and examination can efficiently guide investigations and assist in accurately diagnosing the extent of the knee injury.
- X-ray is the first-line imaging modality, with MRI indicated where significant injury is suspected, such as a popping sensation in the knee, mechanical symptoms or instability.
- Most acute knee injuries can potentially be managed non-operatively, with appropriate early recognition and intervention. GPs can co-ordinate treatment direction and oversee initial physiotherapist-driven rehabilitation.
- GPs have an integral role in patient education, fostering informed decision-making.
- Appropriate specialist referral to orthopaedic surgeons or sports and exercise physicians ensures specialised care for complex and severe injuries.
- A holistic approach — considering the psychological and social factors affecting recovery — allows for comprehensive care that extends beyond physical treatment.
- Regular GP monitoring and follow-up ensures the patient’s treatment plan is effective and adjusted as necessary for optimal recovery.
Start Course
0 Sections

Adult bone disease
This How To Treat course and quiz are approved for 0.5 hour EA and 0.5 hour RP by the RACGP CPD and ACRRM PDP programs for the 2023-2025 triennium. Please read the educational material provided and then complete the quiz and evaluation to earn your Statement of Completion. tr, th { font-size: 16px; font-weight: 400; color: #ffff; padding-top: 12px; } img.wp-image-118064 { margin-right: 300px; padding-bottom: 8px; } img.wp-image-118063 { padding-bottom: 8px; } @media only screen and (max-width: 600px) { .table1{ position: absolute; } } @media only screen and (max-width: 600px) { img.wp-image-118064{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118062{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118063{ width: 300px; } } @media only screen and (max-width: 600px) { th.table2 { padding-top: 320px; } }

RACGP Activity Number: 440595 ACRRM Activity Number: 28342

Key points
- Success in diagnosing and treating bone disease is intellectually challenging.
- Practitioners need to be able to explain BMD tests to patients so a decision can be made regarding whether pharmaceuticals are indicated in addition to lifestyle changes.
- Bone disease can affect anyone, but ageing induced osteoblast senescence on the background of low peak genetic bone mass and ovarian or testicular failure is the most frequent scenario.
- In all cases, it is possible to stop bone loss and increase bone mass by 5-10% over 5-10 years by using pharmaceuticals that have been developed based on our biological evolutionary history.
- These treatments reduce the fracture risk by between 30-50%.
- If necessary, regenerative anabolic therapies that target the osteoblast are also available for high-risk patients; the PBS will pay for these patients only after failure of antiresorptive therapy. Inform all patients of the availability of these therapies because some can afford the cost of the 12-to-18-month therapy on a private prescription.

Start Course
0 Sections

Abnormal results in haematology
This How To Treat course and quiz are approved for 0.5 hour EA and 0.5 hour RP by the RACGP CPD and ACRRM PDP programs for the 2023-2025 triennium. Please read the educational material provided and then complete the quiz and evaluation to earn your Statement of Completion. tr, th { font-size: 16px; font-weight: 400; color: #ffff; padding-top: 12px; } img.wp-image-118064 { margin-right: 300px; padding-bottom: 8px; } img.wp-image-118063 { padding-bottom: 8px; } @media only screen and (max-width: 600px) { .table1{ position: absolute; } } @media only screen and (max-width: 600px) { img.wp-image-118064{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118062{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118063{ width: 300px; } } @media only screen and (max-width: 600px) { th.table2 { padding-top: 320px; } }

RACGP Activity Number: 441828 ACRRM Activity Number: 28374

Key points
- Microcytosis is commonly due to thalassaemia and iron deficiency. The diagnosis of thalassaemia in asymptomatic individuals is generally of no consequence to the patient but may have significant reproductive implications in individuals of child-bearing age if their partner also carries a globin-gene mutation.
- Investigate macrocytosis in individuals where a cause is not evident on clinical assessment; consider haematological malignancies and cobalamin (B12) or folate deficiency in patients not taking drugs which can cause macrocytosis.
- Testing for homocysteine or methylmalonic acid is more sensitive for cobalamin deficiency than measuring serum B12 levels.
- Although a low ferritin is specific for iron deficiency, elevated ferritin is not limited to iron overload and may be seen in several inflammatory states, malignancies, or with liver injury.
- Although most patients with a paraprotein will never develop cancer, these patients will generally require serial testing to detect the small subset who progress to develop myeloma.
Start Course
0 Sections

Achilles tendinopathy
This How To Treat course and quiz are approved for 0.5 hour EA and 0.5 hour RP by the RACGP CPD and ACRRM PDP programs for the 2023-2025 triennium. Please read the educational material provided and then complete the quiz and evaluation to earn your Statement of Completion. tr, th { font-size: 16px; font-weight: 400; color: #ffff; padding-top: 12px; } img.wp-image-118064 { margin-right: 300px; padding-bottom: 8px; } img.wp-image-118063 { padding-bottom: 8px; } @media only screen and (max-width: 600px) { .table1{ position: absolute; } } @media only screen and (max-width: 600px) { img.wp-image-118064{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118062{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118063{ width: 300px; } } @media only screen and (max-width: 600px) { th.table2 { padding-top: 320px; } }

RACGP Activity Number: 417753 ACRRM Activity Number: 28338

Key points
- Achilles tendinopathy is not primarily an inflammatory condition; treatment with rest, ice and anti-inflammatories is not an effective long-term solution.
- The clinical presentation of Achilles tendinopathy is caused by a change in load, which can be subtle or obvious; it is critical to identify this load change so the load can be ameliorated to reduce symptoms.
- Imaging and palpation tenderness are not diagnostic of Achilles tendinopathy; reproduction of pain on loading tests are the best indicators.
- Exercised-based treatment is the gold standard but can take weeks to months to return the person to full activity.
- Passive treatments may offer short-term pain relief; injection therapies are not supported by evidence and do not address the underlying dysfunction.
Start Course
0 Sections

Acne vulgaris
This How To Treat course and quiz are approved for 0.5 hour EA and 0.5 hour RP by the RACGP CPD and ACRRM PDP programs for the 2023-2025 triennium. Please read the educational material provided and then complete the quiz and evaluation to earn your Statement of Completion. tr, th { font-size: 16px; font-weight: 400; color: #ffff; padding-top: 12px; } img.wp-image-118064 { margin-right: 300px; padding-bottom: 8px; } img.wp-image-118063 { padding-bottom: 8px; } @media only screen and (max-width: 600px) { .table1{ position: absolute; } } @media only screen and (max-width: 600px) { img.wp-image-118064{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118062{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118063{ width: 300px; } } @media only screen and (max-width: 600px) { th.table2 { padding-top: 320px; } }

RACGP Activity Number: 634185 ACRRM Activity Number: 31606

Key points
- First-line treatment for mild acne includes topical mono or combined therapy; azaleic acid and topical retinoids are options for patients with concurrent hyperpigmentation.
- First-line treatment for moderate-severe acne includes combined topical therapy with an oral antibiotic.
- Treatment of acne yields results as early as three months; consistent adherence to treatment is key. However, in the absence of response at three months or deterioration prior, referral to a specialist dermatologist is indicated. The PBS does not mandate a time period for which treatments must be trialled before starting oral isotretinoin.
- Consider early specialist referral for consideration of oral isotretinoin in the event of scarring or severe psychological distress.
- Relapses of acne do occur after completing a course of oral isotretinoin and may require a second course. Encourage patients to re-present to their dermatologist if this occurs.
- Do not forget underlying pathologies, hygiene and lifestyle factors, or medications which can exacerbate acne. These may be easier to treat than the acne itself.
Start Course
0 Sections

Acute corneal conditions
This How To Treat course and quiz are approved for 0.5 hour EA and 0.5 hour RP by the RACGP CPD and ACRRM PDP programs for the 2023-2025 triennium. Please read the educational material provided and then complete the quiz and evaluation to earn your Statement of Completion. tr, th { font-size: 16px; font-weight: 400; color: #ffff; padding-top: 12px; } img.wp-image-118064 { margin-right: 300px; padding-bottom: 8px; } img.wp-image-118063 { padding-bottom: 8px; } @media only screen and (max-width: 600px) { .table1{ position: absolute; } } @media only screen and (max-width: 600px) { img.wp-image-118064{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118062{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118063{ width: 300px; } } @media only screen and (max-width: 600px) { th.table2 { padding-top: 320px; } }

RACGP Activity Number: 805444 ACRRM Activity Number: 32910

Key points
- Most corneal conditions can be diagnosed with a careful history of the symptoms and examination for key signs.
- A measurement of the level of vision is mandatory.
- The cornea is accessible with a good light and magnification, aided by topical fluorescein for assessing epithelial defects and aqueous leaks.
- Once a diagnosis is formulated, the appropriate management can be instigated, and follow-up determined by the severity of the condition.
- There is a low threshold for referral for ophthalmic care as the progression of disease can lead to permanent scarring and loss of vision.
Start Course
0 Sections

Acute coronary syndrome
This How To Treat course and quiz are approved for 0.5 hour EA and 0.5 hour RP by the RACGP CPD and ACRRM PDP programs for the 2023-2025 triennium. Please read the educational material provided and then complete the quiz and evaluation to earn your Statement of Completion. tr, th { font-size: 16px; font-weight: 400; color: #ffff; padding-top: 12px; } img.wp-image-118064 { margin-right: 300px; padding-bottom: 8px; } img.wp-image-118063 { padding-bottom: 8px; } @media only screen and (max-width: 600px) { .table1{ position: absolute; } } @media only screen and (max-width: 600px) { img.wp-image-118064{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118062{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118063{ width: 300px; } } @media only screen and (max-width: 600px) { th.table2 { padding-top: 320px; } }

RACGP Activity Number: 522162 ACRRM Activity Number: 30213

Key points
- Cardiac ischaemic chest pain is described as a central pressure sensation on the chest, radiating to the jaw and into the left arm.
- The pain may be retrosternal, deep, diffuse and difficult to localise; it is often associated with nausea and vomiting, fatigue, syncope, diaphoresis, lightheadedness or vague abdominal symptoms in high-risk patients.
- Patients with traditional risk factors, and those with rheumatoid arthritis, HIV/AIDS, chronic kidney disease, non-alcoholic fatty liver disease, mental health disorders, a history of premature menopause or high-risk conditions during pregnancy, are at high risk.
- Initial management in suspected ACS is aspirin and sublingual nitroglycerin (GTN); do not provide antiplatelet or anticoagulation therapy or other therapies such as beta blockers until the diagnosis is confirmed.
- Troponin testing should not delay referral to hospital, and is not indicated in asymptomatic patients.
- Secondary prevention, such as healthy behaviours, intensive risk-factor modification and adherence to proven cardioprotective medications, are critical to reducing new vascular events in patients discharged from hospital with a confirmed diagnosis of ACS.
Start Course
0 Sections

Acute ketoacidosis
This How To Treat course and quiz are approved for 0.5 hour EA and 0.5 hour RP by the RACGP CPD and ACRRM PDP programs for the 2023-2025 triennium. Please read the educational material provided and then complete the quiz and evaluation to earn your Statement of Completion. tr, th { font-size: 16px; font-weight: 400; color: #ffff; padding-top: 12px; } img.wp-image-118064 { margin-right: 300px; padding-bottom: 8px; } img.wp-image-118063 { padding-bottom: 8px; } @media only screen and (max-width: 600px) { .table1{ position: absolute; } } @media only screen and (max-width: 600px) { img.wp-image-118064{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118062{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118063{ width: 300px; } } @media only screen and (max-width: 600px) { th.table2 { padding-top: 320px; } }

RACGP Activity Number: 600850 ACRRM Activity Number: 31236

Key points
- Diabetic ketoacidosis (DKA) is common with type 1 diabetes, affecting up to one in six adults with type 1 diabetes over a 10-year period.
- Euglycaemic ketoacidosis (EKA) is a rare condition triggered by extreme metabolic stress in ketosis-prone individuals (eg, those with diabetes, pregnancy, or who use SGLT2 inhibitors).
- Consider ketoacidosis in the differential diagnosis of sick individuals presenting with non-specific gastrointestinal symptoms, especially those with diabetes.
- Ketoacidosis is easily identified by elevated blood ketone concentrations, which should trigger an emergency plan and urgent hospitalisation.
Start Course
0 Sections

Acute sporting knee injuries
This How To Treat course and quiz are approved for 0.5 hour EA and 0.5 hour RP by the RACGP CPD and ACRRM PDP programs for the 2023-2025 triennium. Please read the educational material provided and then complete the quiz and evaluation to earn your Statement of Completion. tr, th { font-size: 16px; font-weight: 400; color: #ffff; padding-top: 12px; } img.wp-image-118064 { margin-right: 300px; padding-bottom: 8px; } img.wp-image-118063 { padding-bottom: 8px; } @media only screen and (max-width: 600px) { .table1{ position: absolute; } } @media only screen and (max-width: 600px) { img.wp-image-118064{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118062{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118063{ width: 300px; } } @media only screen and (max-width: 600px) { th.table2 { padding-top: 320px; } }

RACGP Activity Number: 1033805 ACRRM Activity Number: 34920

Key points
- Acute knee injuries are common in pivoting and contact sports.
- A thorough history and examination can efficiently guide investigations and assist in accurately diagnosing the extent of the knee injury.
- X-ray is the first-line imaging modality, with MRI indicated where significant injury is suspected, such as a popping sensation in the knee, mechanical symptoms or instability.
- Most acute knee injuries can potentially be managed non-operatively, with appropriate early recognition and intervention. GPs can co-ordinate treatment direction and oversee initial physiotherapist-driven rehabilitation.
- GPs have an integral role in patient education, fostering informed decision-making.
- Appropriate specialist referral to orthopaedic surgeons or sports and exercise physicians ensures specialised care for complex and severe injuries.
- A holistic approach — considering the psychological and social factors affecting recovery — allows for comprehensive care that extends beyond physical treatment.
- Regular GP monitoring and follow-up ensures the patient’s treatment plan is effective and adjusted as necessary for optimal recovery.
Start Course
0 Sections

Adult bone disease
This How To Treat course and quiz are approved for 0.5 hour EA and 0.5 hour RP by the RACGP CPD and ACRRM PDP programs for the 2023-2025 triennium. Please read the educational material provided and then complete the quiz and evaluation to earn your Statement of Completion. tr, th { font-size: 16px; font-weight: 400; color: #ffff; padding-top: 12px; } img.wp-image-118064 { margin-right: 300px; padding-bottom: 8px; } img.wp-image-118063 { padding-bottom: 8px; } @media only screen and (max-width: 600px) { .table1{ position: absolute; } } @media only screen and (max-width: 600px) { img.wp-image-118064{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118062{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118063{ width: 300px; } } @media only screen and (max-width: 600px) { th.table2 { padding-top: 320px; } }

RACGP Activity Number: 440595 ACRRM Activity Number: 28342

Key points
- Success in diagnosing and treating bone disease is intellectually challenging.
- Practitioners need to be able to explain BMD tests to patients so a decision can be made regarding whether pharmaceuticals are indicated in addition to lifestyle changes.
- Bone disease can affect anyone, but ageing induced osteoblast senescence on the background of low peak genetic bone mass and ovarian or testicular failure is the most frequent scenario.
- In all cases, it is possible to stop bone loss and increase bone mass by 5-10% over 5-10 years by using pharmaceuticals that have been developed based on our biological evolutionary history.
- These treatments reduce the fracture risk by between 30-50%.
- If necessary, regenerative anabolic therapies that target the osteoblast are also available for high-risk patients; the PBS will pay for these patients only after failure of antiresorptive therapy. Inform all patients of the availability of these therapies because some can afford the cost of the 12-to-18-month therapy on a private prescription.

1 2 3 … 19 Next »

Start Course
0 Sections

Abnormal results in haematology
This How To Treat course and quiz are approved for 0.5 hour EA and 0.5 hour RP by the RACGP CPD and ACRRM PDP programs for the 2023-2025 triennium. Please read the educational material provided and then complete the quiz and evaluation to earn your Statement of Completion. tr, th { font-size: 16px; font-weight: 400; color: #ffff; padding-top: 12px; } img.wp-image-118064 { margin-right: 300px; padding-bottom: 8px; } img.wp-image-118063 { padding-bottom: 8px; } @media only screen and (max-width: 600px) { .table1{ position: absolute; } } @media only screen and (max-width: 600px) { img.wp-image-118064{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118062{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118063{ width: 300px; } } @media only screen and (max-width: 600px) { th.table2 { padding-top: 320px; } }

RACGP Activity Number: 441828 ACRRM Activity Number: 28374

Key points
- Microcytosis is commonly due to thalassaemia and iron deficiency. The diagnosis of thalassaemia in asymptomatic individuals is generally of no consequence to the patient but may have significant reproductive implications in individuals of child-bearing age if their partner also carries a globin-gene mutation.
- Investigate macrocytosis in individuals where a cause is not evident on clinical assessment; consider haematological malignancies and cobalamin (B12) or folate deficiency in patients not taking drugs which can cause macrocytosis.
- Testing for homocysteine or methylmalonic acid is more sensitive for cobalamin deficiency than measuring serum B12 levels.
- Although a low ferritin is specific for iron deficiency, elevated ferritin is not limited to iron overload and may be seen in several inflammatory states, malignancies, or with liver injury.
- Although most patients with a paraprotein will never develop cancer, these patients will generally require serial testing to detect the small subset who progress to develop myeloma.
Start Course
0 Sections

Achilles tendinopathy
This How To Treat course and quiz are approved for 0.5 hour EA and 0.5 hour RP by the RACGP CPD and ACRRM PDP programs for the 2023-2025 triennium. Please read the educational material provided and then complete the quiz and evaluation to earn your Statement of Completion. tr, th { font-size: 16px; font-weight: 400; color: #ffff; padding-top: 12px; } img.wp-image-118064 { margin-right: 300px; padding-bottom: 8px; } img.wp-image-118063 { padding-bottom: 8px; } @media only screen and (max-width: 600px) { .table1{ position: absolute; } } @media only screen and (max-width: 600px) { img.wp-image-118064{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118062{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118063{ width: 300px; } } @media only screen and (max-width: 600px) { th.table2 { padding-top: 320px; } }

RACGP Activity Number: 417753 ACRRM Activity Number: 28338

Key points
- Achilles tendinopathy is not primarily an inflammatory condition; treatment with rest, ice and anti-inflammatories is not an effective long-term solution.
- The clinical presentation of Achilles tendinopathy is caused by a change in load, which can be subtle or obvious; it is critical to identify this load change so the load can be ameliorated to reduce symptoms.
- Imaging and palpation tenderness are not diagnostic of Achilles tendinopathy; reproduction of pain on loading tests are the best indicators.
- Exercised-based treatment is the gold standard but can take weeks to months to return the person to full activity.
- Passive treatments may offer short-term pain relief; injection therapies are not supported by evidence and do not address the underlying dysfunction.
Start Course
0 Sections

Acne vulgaris
This How To Treat course and quiz are approved for 0.5 hour EA and 0.5 hour RP by the RACGP CPD and ACRRM PDP programs for the 2023-2025 triennium. Please read the educational material provided and then complete the quiz and evaluation to earn your Statement of Completion. tr, th { font-size: 16px; font-weight: 400; color: #ffff; padding-top: 12px; } img.wp-image-118064 { margin-right: 300px; padding-bottom: 8px; } img.wp-image-118063 { padding-bottom: 8px; } @media only screen and (max-width: 600px) { .table1{ position: absolute; } } @media only screen and (max-width: 600px) { img.wp-image-118064{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118062{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118063{ width: 300px; } } @media only screen and (max-width: 600px) { th.table2 { padding-top: 320px; } }

RACGP Activity Number: 634185 ACRRM Activity Number: 31606

Key points
- First-line treatment for mild acne includes topical mono or combined therapy; azaleic acid and topical retinoids are options for patients with concurrent hyperpigmentation.
- First-line treatment for moderate-severe acne includes combined topical therapy with an oral antibiotic.
- Treatment of acne yields results as early as three months; consistent adherence to treatment is key. However, in the absence of response at three months or deterioration prior, referral to a specialist dermatologist is indicated. The PBS does not mandate a time period for which treatments must be trialled before starting oral isotretinoin.
- Consider early specialist referral for consideration of oral isotretinoin in the event of scarring or severe psychological distress.
- Relapses of acne do occur after completing a course of oral isotretinoin and may require a second course. Encourage patients to re-present to their dermatologist if this occurs.
- Do not forget underlying pathologies, hygiene and lifestyle factors, or medications which can exacerbate acne. These may be easier to treat than the acne itself.
Start Course
0 Sections

Acute corneal conditions
This How To Treat course and quiz are approved for 0.5 hour EA and 0.5 hour RP by the RACGP CPD and ACRRM PDP programs for the 2023-2025 triennium. Please read the educational material provided and then complete the quiz and evaluation to earn your Statement of Completion. tr, th { font-size: 16px; font-weight: 400; color: #ffff; padding-top: 12px; } img.wp-image-118064 { margin-right: 300px; padding-bottom: 8px; } img.wp-image-118063 { padding-bottom: 8px; } @media only screen and (max-width: 600px) { .table1{ position: absolute; } } @media only screen and (max-width: 600px) { img.wp-image-118064{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118062{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118063{ width: 300px; } } @media only screen and (max-width: 600px) { th.table2 { padding-top: 320px; } }

RACGP Activity Number: 805444 ACRRM Activity Number: 32910

Key points
- Most corneal conditions can be diagnosed with a careful history of the symptoms and examination for key signs.
- A measurement of the level of vision is mandatory.
- The cornea is accessible with a good light and magnification, aided by topical fluorescein for assessing epithelial defects and aqueous leaks.
- Once a diagnosis is formulated, the appropriate management can be instigated, and follow-up determined by the severity of the condition.
- There is a low threshold for referral for ophthalmic care as the progression of disease can lead to permanent scarring and loss of vision.

Start Course
0 Sections

Abnormal results in haematology
This How To Treat course and quiz are approved for 0.5 hour EA and 0.5 hour RP by the RACGP CPD and ACRRM PDP programs for the 2023-2025 triennium. Please read the educational material provided and then complete the quiz and evaluation to earn your Statement of Completion. tr, th { font-size: 16px; font-weight: 400; color: #ffff; padding-top: 12px; } img.wp-image-118064 { margin-right: 300px; padding-bottom: 8px; } img.wp-image-118063 { padding-bottom: 8px; } @media only screen and (max-width: 600px) { .table1{ position: absolute; } } @media only screen and (max-width: 600px) { img.wp-image-118064{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118062{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118063{ width: 300px; } } @media only screen and (max-width: 600px) { th.table2 { padding-top: 320px; } }

RACGP Activity Number: 441828 ACRRM Activity Number: 28374

Key points
- Microcytosis is commonly due to thalassaemia and iron deficiency. The diagnosis of thalassaemia in asymptomatic individuals is generally of no consequence to the patient but may have significant reproductive implications in individuals of child-bearing age if their partner also carries a globin-gene mutation.
- Investigate macrocytosis in individuals where a cause is not evident on clinical assessment; consider haematological malignancies and cobalamin (B12) or folate deficiency in patients not taking drugs which can cause macrocytosis.
- Testing for homocysteine or methylmalonic acid is more sensitive for cobalamin deficiency than measuring serum B12 levels.
- Although a low ferritin is specific for iron deficiency, elevated ferritin is not limited to iron overload and may be seen in several inflammatory states, malignancies, or with liver injury.
- Although most patients with a paraprotein will never develop cancer, these patients will generally require serial testing to detect the small subset who progress to develop myeloma.
Start Course
0 Sections

Achilles tendinopathy
This How To Treat course and quiz are approved for 0.5 hour EA and 0.5 hour RP by the RACGP CPD and ACRRM PDP programs for the 2023-2025 triennium. Please read the educational material provided and then complete the quiz and evaluation to earn your Statement of Completion. tr, th { font-size: 16px; font-weight: 400; color: #ffff; padding-top: 12px; } img.wp-image-118064 { margin-right: 300px; padding-bottom: 8px; } img.wp-image-118063 { padding-bottom: 8px; } @media only screen and (max-width: 600px) { .table1{ position: absolute; } } @media only screen and (max-width: 600px) { img.wp-image-118064{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118062{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118063{ width: 300px; } } @media only screen and (max-width: 600px) { th.table2 { padding-top: 320px; } }

RACGP Activity Number: 417753 ACRRM Activity Number: 28338

Key points
- Achilles tendinopathy is not primarily an inflammatory condition; treatment with rest, ice and anti-inflammatories is not an effective long-term solution.
- The clinical presentation of Achilles tendinopathy is caused by a change in load, which can be subtle or obvious; it is critical to identify this load change so the load can be ameliorated to reduce symptoms.
- Imaging and palpation tenderness are not diagnostic of Achilles tendinopathy; reproduction of pain on loading tests are the best indicators.
- Exercised-based treatment is the gold standard but can take weeks to months to return the person to full activity.
- Passive treatments may offer short-term pain relief; injection therapies are not supported by evidence and do not address the underlying dysfunction.
Start Course
0 Sections

Acne vulgaris
This How To Treat course and quiz are approved for 0.5 hour EA and 0.5 hour RP by the RACGP CPD and ACRRM PDP programs for the 2023-2025 triennium. Please read the educational material provided and then complete the quiz and evaluation to earn your Statement of Completion. tr, th { font-size: 16px; font-weight: 400; color: #ffff; padding-top: 12px; } img.wp-image-118064 { margin-right: 300px; padding-bottom: 8px; } img.wp-image-118063 { padding-bottom: 8px; } @media only screen and (max-width: 600px) { .table1{ position: absolute; } } @media only screen and (max-width: 600px) { img.wp-image-118064{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118062{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118063{ width: 300px; } } @media only screen and (max-width: 600px) { th.table2 { padding-top: 320px; } }

RACGP Activity Number: 634185 ACRRM Activity Number: 31606

Key points
- First-line treatment for mild acne includes topical mono or combined therapy; azaleic acid and topical retinoids are options for patients with concurrent hyperpigmentation.
- First-line treatment for moderate-severe acne includes combined topical therapy with an oral antibiotic.
- Treatment of acne yields results as early as three months; consistent adherence to treatment is key. However, in the absence of response at three months or deterioration prior, referral to a specialist dermatologist is indicated. The PBS does not mandate a time period for which treatments must be trialled before starting oral isotretinoin.
- Consider early specialist referral for consideration of oral isotretinoin in the event of scarring or severe psychological distress.
- Relapses of acne do occur after completing a course of oral isotretinoin and may require a second course. Encourage patients to re-present to their dermatologist if this occurs.
- Do not forget underlying pathologies, hygiene and lifestyle factors, or medications which can exacerbate acne. These may be easier to treat than the acne itself.
Start Course
0 Sections

Acute corneal conditions
This How To Treat course and quiz are approved for 0.5 hour EA and 0.5 hour RP by the RACGP CPD and ACRRM PDP programs for the 2023-2025 triennium. Please read the educational material provided and then complete the quiz and evaluation to earn your Statement of Completion. tr, th { font-size: 16px; font-weight: 400; color: #ffff; padding-top: 12px; } img.wp-image-118064 { margin-right: 300px; padding-bottom: 8px; } img.wp-image-118063 { padding-bottom: 8px; } @media only screen and (max-width: 600px) { .table1{ position: absolute; } } @media only screen and (max-width: 600px) { img.wp-image-118064{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118062{ width: 300px; } } @media only screen and (max-width: 600px) { img.wp-image-118063{ width: 300px; } } @media only screen and (max-width: 600px) { th.table2 { padding-top: 320px; } }

RACGP Activity Number: 805444 ACRRM Activity Number: 32910

Key points
- Most corneal conditions can be diagnosed with a careful history of the symptoms and examination for key signs.
- A measurement of the level of vision is mandatory.
- The cornea is accessible with a good light and magnification, aided by topical fluorescein for assessing epithelial defects and aqueous leaks.
- Once a diagnosis is formulated, the appropriate management can be instigated, and follow-up determined by the severity of the condition.
- There is a low threshold for referral for ophthalmic care as the progression of disease can lead to permanent scarring and loss of vision.

1 2 3 … 38 Next »

Join AusDoc today for convenient, free access to medical education and CPD hours

1Membership Type

2Account Details

3Personal Information

Profile Type*

To ensure you get the right membership, please select your vocation:

Medical Practitioner

Allied Health

Medical Student

Pharma Employee

Other

Already a member? Click here to log in.

Joining is free and easy for AHPRA-registered healthcare professionals. You’re close to being able to access the most up to date news curated especially for Australian doctors.

Joining is free and easy for AHPRA-registered HCPs. You’re close to being able to access the most up-to-date news

Joining is free and easy for all Australian medical students with a university email address. You’re close to being able to access the most up to date medical and clinical news for medical practitioners.

Please note: Our site and its content has been designed specifically to meet the needs of AHPRA-registered healthcare professionals. If you are not registered with AHPRA or a pharmaceutical industry professional, your account request will go to our Customer Service team prior to access being granted.

Please note: Our site and its content has been designed specifically to meet the specialised needs of AHPRA-registered healthcare professionals. If you are not registered with AHPRA, your application will go to our Customer Support team prior to gaining access.

Email*

Enter Email Confirm Email

Password*

Enter Password Confirm Password

Strength indicator

AHPRA Number*

Can't remember your AHPRA Number?

University*

Graduation Year*

Company Name*

First Line Products

Second Line Products

Third Line Products

CAPTCHA

This field is hidden when viewing the form

Username

Placeholder.

The below details are matched from AHPRA. If you need to make any changes, please contact our customer service team.

Salutation

First Name*

Last Name*

Profession*

Specialty

Profession Type*

Street Name*

Suburb*

State*

Postcode*

Country*

Phone Number*

Keep me up to date

Join the Australian Doctor email newsletter

Join the How to treat email newsletter

Join the Australian Specialist newsletter

Consent*

I agree to the Terms of Service

Abbott
Acnatac
Acne
ACRRM
Actikerall
ADG
Advantan
Aimovig
Aklief
Aleve
Alfamino
Allertine
Alvesco
Amgen Osteoperosis
Amgen-Prime Awards
AMPS
Andexxa
Aptamil
Asthma Australia
Astra Health AI
Atectura
Audika
AusDoc
Australian Dementia Network Research Forum
Australian Eggs
Australian Psychological Society
Australian Teletrials Program
Avant
Belsomra
Betmiga
Beyfortus
Bijuva
Biocelect
Black Dog Institute
Bowel Cancer Australia
Bp Premier
Breztri
Brimica
Brintellix
Bupa Australia
Buvidal
Cancer council Australia
Cancer Institute NSW
Care Pharma
Cervidil
Champix
Chiesi Portfolio
Cialis
Clinical Research
Codral
Comirnaty
Contrave
COPD
COSA
Coveram
Creon
Crestor
Cutcher & Neale
Dairy Australia
Daivobet
Department of Veteran Affairs
Dexcom
DiagnostiCare
Digital Test
Dr Falk Pharma drivetime Podcasts
Durotocin
Dymista
Ebglyss
Eczema Hub
Elidel
Eliquis
Emgality
Enerzair
Epipen
Estrogel Pro
Eucalyptus
Exforge
Ferinject
Fiasp
Fleurstat
Fluzone GP
Fluzone Pharm
Forxiga
Fostair
Freelite
Gaviscon
geneType
Glugeneron
GSK
Health Pathways
Healthcare-Pulse-Report
HealthPathways
Healthshare
Heart Foundation
Helix
Helm
HeyDay Medical
Imojev
IMPLANON NXT
Jardiance
Kiamera
Kidney Health Australia
Kooyong Group
Kyleena
Kyowa Kirin
Lagevrio
Latuda
Leo Pharma
Leqvio
Levin
Lite n' Easy
Lundbeck
Lung Foundation Australia
MedicAlert
MedicineInsight
MediQo
MedReleaf
Medtronic
Menarini
Menquadfi
Minirin
MIPS
Mirena
Mito Foundation
Moderna Atlas
Monofer
Montu
Mounjaro
Nasonex
NDSS
Nerva
Nicovape Q
Norgesic
Novalac
Novartis
Novasure
NSW Government
Nurofen
Nutrition Research Australia
OPDIVO
Optifast
Optisulin
Organon
Ozempic
PADCEV
Palexia
Paxlovid
Peptamen Junior
Pfizer Connect
Pradaxa
Precision Radiology WA Trust
Prevenar
Professional Certificates
Prolia
Provider Connect Australia
Psoriasis Hub
Psychiatry
Qiara
Quality Use of Medicines Alliance
Quit Centre
Rabipur
Relpax
Repatha
Rikodeine
Roche Diagnostics
Ryeqo
Ryman
Ryzodeg
Ryzodeg - Survey
Sandrena
Saxenda
Seretide
Servier Brand Hub
Sleep Association
Slinda
Soolantra
Spikevax
Spiolto Respimat
Spiriva (Asthma)
Spiriva (COPD)
Steglatro slash Januvia
Syneo
Systane
Terrosa
The Binding Site
Therapeutic Guidelines
Toujeo
Trajenta
Trelegy Ellipta
Trimbow
Trulicity
Ultibro
Ultibro Breezhaler
Uniting
Updoc
Utrogestan
Valdoxan
Vaxchora
Ventolin
Veoza
Visanne
Vivaxim
Vyndamax
Wegovy
Westmead Fertility Centre
Xarelto
Xigduo
Xolair
XV LVAS
Zolgensma

Abbott
Acnatac
Acne
ACRRM
Actikerall
ADG
Advantan
Aimovig
Aklief
Aleve
Alfamino
Allertine
Alvesco
Amgen Osteoperosis
Amgen-Prime Awards
AMPS
Andexxa
Aptamil
Asthma Australia
Astra Health AI
Atectura
Audika
AusDoc
Australian Dementia Network Research Forum
Australian Eggs
Australian Psychological Society
Australian Teletrials Program
Avant
Belsomra
Betmiga
Beyfortus
Bijuva
Biocelect
Black Dog Institute
Bowel Cancer Australia
Bp Premier
Breztri
Brimica
Brintellix
Bupa Australia
Buvidal
Cancer council Australia
Cancer Institute NSW
Care Pharma
Cervidil
Champix
Chiesi Portfolio
Cialis
Clinical Research
Codral
Comirnaty
Contrave
COPD
COSA
Coveram
Creon
Crestor
Cutcher & Neale
Dairy Australia
Daivobet
Department of Veteran Affairs
Dexcom
DiagnostiCare
Digital Test
Dr Falk Pharma drivetime Podcasts
Durotocin
Dymista
Ebglyss
Eczema Hub
Elidel
Eliquis
Emgality
Enerzair
Epipen
Estrogel Pro
Eucalyptus
Exforge
Ferinject
Fiasp
Fleurstat
Fluzone GP
Fluzone Pharm
Forxiga
Fostair
Freelite
Gaviscon
geneType
Glugeneron
GSK
Health Pathways
Healthcare-Pulse-Report
HealthPathways
Healthshare
Heart Foundation
Helix
Helm
HeyDay Medical
Imojev
IMPLANON NXT
Jardiance
Kiamera
Kidney Health Australia
Kooyong Group
Kyleena
Kyowa Kirin
Lagevrio
Latuda
Leo Pharma
Leqvio
Levin
Lite n' Easy
Lundbeck
Lung Foundation Australia
MedicAlert
MedicineInsight
MediQo
MedReleaf
Medtronic
Menarini
Menquadfi
Minirin
MIPS
Mirena
Mito Foundation
Moderna Atlas
Monofer
Montu
Mounjaro
Nasonex
NDSS
Nerva
Nicovape Q
Norgesic
Novalac
Novartis
Novasure
NSW Government
Nurofen
Nutrition Research Australia
OPDIVO
Optifast
Optisulin
Organon
Ozempic
PADCEV
Palexia
Paxlovid
Peptamen Junior
Pfizer Connect
Pradaxa
Precision Radiology WA Trust
Prevenar
Professional Certificates
Prolia
Provider Connect Australia
Psoriasis Hub
Psychiatry
Qiara
Quality Use of Medicines Alliance
Quit Centre
Rabipur
Relpax
Repatha
Rikodeine
Roche Diagnostics
Ryeqo
Ryman
Ryzodeg
Ryzodeg - Survey
Sandrena
Saxenda
Seretide
Servier Brand Hub
Sleep Association
Slinda
Soolantra
Spikevax
Spiolto Respimat
Spiriva (Asthma)
Spiriva (COPD)
Steglatro slash Januvia
Syneo
Systane
Terrosa
The Binding Site
Therapeutic Guidelines
Toujeo
Trajenta
Trelegy Ellipta
Trimbow
Trulicity
Ultibro
Ultibro Breezhaler
Uniting
Updoc
Utrogestan
Valdoxan
Vaxchora
Ventolin
Veoza
Visanne
Vivaxim
Vyndamax
Wegovy
Westmead Fertility Centre
Xarelto
Xigduo
Xolair
XV LVAS
Zolgensma

Abbott
Acnatac
Acne
ACRRM
Actikerall
ADG
Advantan
Aimovig
Aklief
Aleve
Alfamino
Allertine
Alvesco
Amgen Osteoperosis
Amgen-Prime Awards
AMPS
Andexxa
Aptamil
Asthma Australia
Astra Health AI
Atectura
Audika
AusDoc
Australian Dementia Network Research Forum
Australian Eggs
Australian Psychological Society
Australian Teletrials Program
Avant
Belsomra
Betmiga
Beyfortus
Bijuva
Biocelect
Black Dog Institute
Bowel Cancer Australia
Bp Premier
Breztri
Brimica
Brintellix
Bupa Australia
Buvidal
Cancer council Australia
Cancer Institute NSW
Care Pharma
Cervidil
Champix
Chiesi Portfolio
Cialis
Clinical Research
Codral
Comirnaty
Contrave
COPD
COSA
Coveram
Creon
Crestor
Cutcher & Neale
Dairy Australia
Daivobet
Department of Veteran Affairs
Dexcom
DiagnostiCare
Digital Test
Dr Falk Pharma drivetime Podcasts
Durotocin
Dymista
Ebglyss
Eczema Hub
Elidel
Eliquis
Emgality
Enerzair
Epipen
Estrogel Pro
Eucalyptus
Exforge
Ferinject
Fiasp
Fleurstat
Fluzone GP
Fluzone Pharm
Forxiga
Fostair
Freelite
Gaviscon
geneType
Glugeneron
GSK
Health Pathways
Healthcare-Pulse-Report
HealthPathways
Healthshare
Heart Foundation
Helix
Helm
HeyDay Medical
Imojev
IMPLANON NXT
Jardiance
Kiamera
Kidney Health Australia
Kooyong Group
Kyleena
Kyowa Kirin
Lagevrio
Latuda
Leo Pharma
Leqvio
Levin
Lite n' Easy
Lundbeck
Lung Foundation Australia
MedicAlert
MedicineInsight
MediQo
MedReleaf
Medtronic
Menarini
Menquadfi
Minirin
MIPS
Mirena
Mito Foundation
Moderna Atlas
Monofer
Montu
Mounjaro
Nasonex
NDSS
Nerva
Nicovape Q
Norgesic
Novalac
Novartis
Novasure
NSW Government
Nurofen
Nutrition Research Australia
OPDIVO
Optifast
Optisulin
Organon
Ozempic
PADCEV
Palexia
Paxlovid
Peptamen Junior
Pfizer Connect
Pradaxa
Precision Radiology WA Trust
Prevenar
Professional Certificates
Prolia
Provider Connect Australia
Psoriasis Hub
Psychiatry
Qiara
Quality Use of Medicines Alliance
Quit Centre
Rabipur
Relpax
Repatha
Rikodeine
Roche Diagnostics
Ryeqo
Ryman
Ryzodeg
Ryzodeg - Survey
Sandrena
Saxenda
Seretide
Servier Brand Hub
Sleep Association
Slinda
Soolantra
Spikevax
Spiolto Respimat
Spiriva (Asthma)
Spiriva (COPD)
Steglatro slash Januvia
Syneo
Systane
Terrosa
The Binding Site
Therapeutic Guidelines
Toujeo
Trajenta
Trelegy Ellipta
Trimbow
Trulicity
Ultibro
Ultibro Breezhaler
Uniting
Updoc
Utrogestan
Valdoxan
Vaxchora
Ventolin
Veoza
Visanne
Vivaxim
Vyndamax
Wegovy
Westmead Fertility Centre
Xarelto
Xigduo
Xolair
XV LVAS
Zolgensma

Medical education right at your fingertips

Enhance your clinical expertise anytime, anywhere

Why use AusDoc CPD?

On-demand access anytime, anywhere.

CPD at no cost to you.

Created for Australian GPs by local specialists.

Up-to-date with current best practices.

Wide range of relevant general practice topics.

Automatic tracking of CPD hours for HTT courses.

Consolidate your knowledge and earn accredited CPD hours effortlessly with our How To Treat Courses—all for free.

Sharpen your diagnostic skills with our Self-Recorded Spot Diagnosis Cases

Stay up to date with the industry through our Self-Directed Learning Modules